### Calcium Channel Blockers Treatment Selector

**Charts revised December 2023. Full information available at www.hiv-druginteractions.org**

<table>
<thead>
<tr>
<th>Calcium Channel Blockers</th>
<th>ATV/c</th>
<th>ATV/r</th>
<th>DRV/c</th>
<th>DRV/r</th>
<th>LPV/r</th>
<th>DOR</th>
<th>EFV</th>
<th>ETV</th>
<th>NVP</th>
<th>RPV</th>
<th>FTR</th>
<th>LEN</th>
<th>MVC</th>
<th>BIC/</th>
<th>CAB</th>
<th>CAB/</th>
<th>DTG</th>
<th>EVG/c</th>
<th>EVG/c</th>
<th>RAL</th>
<th>FTC/</th>
<th>FTC/</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine</td>
<td>↑↑</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>↑↑</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Felodipine</td>
<td>↑↑</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Lacidipine</td>
<td>↑↑</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Lercanidipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Nicardipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Nisoldipine</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Verapamil</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
</tbody>
</table>

### Interactions with CAB/RPV long acting injections
Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

**Interactions with Lenacapavir**
Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

**Interactions with Ibalizumab**
None

### Colour Legend
- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity.

### Text Legend
- ↑ Potential increased exposure of the antihypertensive
- ↓ Potential decreased exposure of the antihypertensive
- ↔ No significant effect
- ♥ One or both drugs may cause QT and/or PR prolongation.
- ECG monitoring is advised if coadministered with atazanavir or lopinavir.
- Caution is advised with ritonavir. ECG monitoring is advised with fostemsavir and drugs with a known QT prolongation risk.

### Notes
- Coadministration may increase bictegravir concentrations; no effect on emtricitabine or tenofovir alafenamide is expected.
- Coadministration may increase bictegravir and tenofovir alafenamide concentrations; no effect on emtricitabine is expected.
- Coadministration could potentially increase the absorption of tenofovir alafenamide, thereby increasing the systemic concentration of tenofovir.
- Coadministration could potentially increase the absorption of tenofovir-DF, thereby increasing the systemic concentration of tenofovir. Monitoring of tenofovir-associated adverse reactions, including frequent renal monitoring, is recommended.

---

Interactions with Abacavir (ABC), Lamivudine (3TC), Tenofovir-DF (TDF) or Zidovudine (ZDV)
ABC: No clinically relevant interactions expected.
3TC: No clinically relevant interactions expected.
TDF: Verapamil could potentially increase absorption of tenofovir-DF (d).
ZDV: No clinically relevant interactions expected.

---

**Abbreviations**
- ATN atazanavir
- DRV darunavir
- DRV/r ritonavir-boosted darunavir
- LPV lopinavir
- NVP nevirapine
- EFV efavirenz
- ETV etravirine
- FTC emtricitabine
- TAF tenofovir alafenamide
- DF, F/TAF DF (TDF) or Zidovudine (ZDV)
- BIC bictegravir
- CAB raltegravir
- MVC maraviroc
- ABC atazanavir
- F/TAF cobicistat
- DTG dolutegravir
- EVG/c rilpivirine
- RAL raltegravir
- EVG/c/r ritonavir-boosted rilpivirine
- TDF tenofovir
- FTC/ TAF tenofovir alafenamide

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

**For personal use only. Not for distribution.**